secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001140361-25-026132
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants RMAT designation to Rocket Pharma's RP-A601 gene therapy for PKP2-ACM
--------------------------------------------------------------------------------

- FDA granted RMAT designation for RP-A601 (AAV-based gene therapy) for PKP2-arrhythmogenic cardiomyopathy.
- RMAT provides expedited FDA review, early interactions, and potential accelerated approval.
- Phase 1 data: two patients with low baseline PKP2 showed 110% and 398% increases in protein expression.
- Improvements in right ventricular function, ventricular arrhythmias, and KCCQ-12 scores (34-41 pts).
- Fifth RMAT designation for Rocket; favorable safety with no dose-limiting toxicities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125026132/0001140361-25-026132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036125026132/ef20052120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-026132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer